alexa
Reach Us +1-217-403-9671
Anti-Rheumatic Activity of Celecoxib and Methotrexate in Collagen Induced Arthritis: A Proteomic Approach | OMICS International
ISSN: 2153-0645
Journal of Pharmacogenomics & Pharmacoproteomics

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Anti-Rheumatic Activity of Celecoxib and Methotrexate in Collagen Induced Arthritis: A Proteomic Approach

Rajasekhar Tulasi Baru1* and Prasanth Bitla2

1Granada Pharma Ltd., Granada, PO BOX 11797, Riyadh 3939, Saudi Arabia

2University of Hyderabad, Prof CR Rao Rd, CUC, Gachibowli, Hyderabad, Telangana 500046, India

*Corresponding Author:
Rajasekhar Tulasi Baru
Granada Pharma Ltd., Granada
PO BOX 11797, Riyadh 3939
Saudi Arabia
Tel: 966-583956618
E-mail: [email protected]

Received Date: September 26, 2017; Accepted Date: October 09, 2017; Published Date: October 12, 2017

Citation: Baru RT, Bitla P (2017) Anti-Rheumatic Activity of Celecoxib and Methotrexate in Collagen Induced Arthritis: A Proteomic Approach. J Pharmacogenomics Pharmacoproteomics 8:175. doi: 10.4172/2153-0645.1000175

Copyright: © 2017 Rajasekhar TB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Pharmacogenomics & Pharmacoproteomics

Abstract

Rheumatoid Arthritis (RA) is a chronic inflammatory disorder of the synovial membrane that results in the destruction of bone and cartilage in affected joints. In order to identify novel disease-related proteins and candidate biomarkers, we analyzed the changes in the serum proteome profiles of rats with RA that were treated with a COX-2 inhibitor, celecoxib and a DMARD, methotrexate. Serum samples were collected from the RA rats before and after the drug treatment. Following immunodepletion of major proteins, the proteins were digested. The proteins were identified using MALDI-TOF mass spectrometry. Several proteins are identified and the proteins that play a key role in RA are studied. These proteins are inhibited differentially by celecoxib and methotrexate. Although some of the proteins are known to be related to RA, several are currently unknown with respect to their relationship to RA and may be involved in the development of this disease. Our results may contribute to the identification of novel disease related proteins and enhance the understanding of the pathogenesis of RA.

Introduction

Rheumatoid Arthritis (RA) is an inflammatory condition with multi-organ involvement. It is a relatively common condition and about 0.5% to 1% of the population is effected [1]. Evidence suggests that it becomes more prevalent correlating with increasing latitude and when it is compared between rural to urban populations [2]. RA is destructive and it affects the small joints predominantly. Increased prevalence of atherosclerotic disease and reduced participation in society are observed in RA patients [3]. Reduced work capacity as a result of RA puts an indirect cost to society and has been estimated to be as high as € 41.6 billion in the United States and € 45.3 billion in Europe [4].

It was initially thought that RA was infection driven that led to the use of gold and sulpha drugs with limited success. As research progressed in the treatment of RA, use of steroids as therapeutic agents gained popularity among physicians [5]. As our understanding of the disease has improved, we have moved on to more targeted therapies. The onset of RA is thought to be dependent on both environmental and genetic factors. Of these, the major modifiable environmental risk factor identified is that of smoking [6]. Therapies currently employed to combat RA include traditional treatments such as glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs), and diseasemodifying antirheumatic drugs (DMARDs), classified broadly as synthetic (encompassing the traditional DMARDs and newer therapies such as JAK-2 inhibitors) and biological drugs.

Marked symptomatic relief was seen with the introduction of NSAIDs. Though not a DMARD, its beneficial effects have been long documented with Willow and poplar bark, the substrates for salicylic acid, commonly used in the treatment of inflammatory arthopathies [7]. Aspirin was in use by the early twentieth century in the treatment of RA, making it the oldest of the medications currently in use [8]. We now have a vast selection of NSAIDs available, all working to inhibit the cyclo-oxygenase pathway. Prostaglandins are made by two different enzymes, cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). The prostaglandins made by the two different enzymes have slightly different effects on the body. COX-2 inhibitors are NSAIDs that selectively block the COX-2 enzyme and not the COX-1 enzyme. Blocking this enzyme impedes the production of prostaglandins by the COX-2 which causes the pain, swelling and other painful conditions. Because they selectively block the COX-2 enzyme and not the COX-1 enzyme, these drugs are uniquely different from traditional NSAIDs which usually block both COX-1 and COX-2 enzymes. Although NSAIDs are effective analgesics, they do not have any demonstrable effect on disease course and further they have side effects that include gastric irritation and nephrotoxicity [9].

The term DMARD (Disease modifying anti-rheumatic drug) is applied to medications which can alter the course of disease and thus prevent joint erosion [10]. The mechanisms through which DMARDs act are varied but a collective outcome is to help stem the destructive process of intertwined inflammatory cascades resulting in the degradation of soft tissue, cartilage and bone.

The advent of proteomics technologies has enabled large-scale analysis of proteins to identify biomarkers that delineate disease subtypes of rheumatoid arthritis, and to gain insights into the mechanisms underlying these subtypes. The aim of this study is to identify proteins that are differentially expressed between control and arthritis sera and to further look at the protein profiles of the COX-2 inhibitor, celecoxib vs DMARD, methotrexate, and treated sera profiles by proteomics approach. The aim of this study is to figure out differences at the protein level for the above two drugs since celecoxib is known for its anti-inflammatory properties in arthritis and methotrexate is known to target the cytokines.

Materials and Methods

Unless otherwise noted, all chemicals were purchased from Sigma (Sigma Chemicals, St. Louis, MO) and were of analytical grade. Trypsin is purchased from Promega (sequencing grade modified trypsin, Catalog No. V5111, Mannheim, Germany).

Animals

Male Lewis rats (150-180 gm) were obtained from Harlan Sprague Dawley (Indianapolis, IN), housed in micro isolator cages (Lab Products, Maywood, NJ), and supplied with sterilized standard rodent chow diet and acidified water (pH 2.8-3.0). The animals were handled under clean conditions and were acclimated to the new environment for a week before use.

Preparation of type II collagen

Native type II collagen was extracted from bovine articular cartilage, after digestion with papain. The extraction and purification procedures for collagen have been described previously [11]. The purified preparation was stored in O.05M acetic acid at -20°C.

Induction of arthritis

The mean body weight and mean hind paw volume of rats in each group were very similar at the start of every experiment. Type II collagen arthritis was induced by an intradermal injection, at the base of the tail, of an emulsion of 100 pg bovine type II collagen in 0.05M acetic acid with an equivalent volume of incomplete Freund’s adjuvant (ICFA).

Intravenous treatment with the antigens

Type II collagen (stock solution in O.05M acetic acid) was adjusted to pH 7, diluted with phosphate buffered saline (PBS), and stirred vigorously at 0°C to avoid any possible clumping. The collagen solution (0.5 mg) was injected intravenously into the tail vein of each rat, without the use of any anesthetic and with precautions to minimize trauma. The denatured type II collagen solution was prepared by heating native type II collagen at 60°C for 30 minutes. Some animals received M tuberculosis (2 mg in PBS) intravenously in the same fashion. These treatments were given to rats either 3 days prior to or 7 or 10 days after the immunization for induction of arthritis.

Evaluation of inflammatory response

The development and severity of arthritis were mainly assessed by the quantitation of hind paw swelling of the rats. Both hind paws of each rat were dipped in a mercury bath and the volume of displacement of mercury was measured twice a week [12,13]. Along with the swelling of hind paws, visual disfigurement, restricted movement, and radiologic evaluation of the joints were taken into consideration to determine the degree of arthritis.

Administration of celecoxib and methotrexate to arthritic rats

Seven rats with collagen induced arthritis were given 10 mg/kg per day of celecoxib for two weeks from the onset of arthritis. Seven rats with collagen induced arthritis were given 10 mg/kg per day of methotrexate for two weeks from the onset of arthritis. Seven rats with collagen induced arthritis served as normal controls and are not given either of these drugs.

Serum protein solubilization and sample application

Serum collected from normal rats, arthritic rats, and arthritic rats treated with celecoxib and arthritic rats treated with methotrexate, were processed as follows. The serum sample is passed through albumin/globulin removal columns (commercially supplied by Amersham). The eluate from the column is collected and the protein amount is determined. The protein is suitably solubilized in the 2-d gel buffers. To each 4-7 IPG strip, 300 μg protein is added and the strips are allowed to rehydrate overnight along with the sample.

2-d Gel electrophoresis

The IPG strips are rehydrated with the sample overnight and electrophoresis is carried out in the first dimension the following day. The strips are then placed on a regular SDS-PAGE gel and the electrophoresis is carried out in the second dimension. The gels are then silver stained.

2-d Gel analysis

After 2-D gels are stained, the protein patterns are digitized and analyzed across multiple gels (Control rat sera, arthritis rat sera, celecoxib treated rat sera and methotrexate treated rat sera) by Computer-assisted image analysis which is an indispensable tool for the evaluation of complex 2-D gels. PDQuest™ 2-D analysis software from Biorad is used to pick the spots and compare the spots of interest across the gels.

Spot picking, protein digestion and MALDI-TOF (Matrix Assisted Laser Desorption Ionization-Time of Flight) analysis

Using the Ettan spot handling workstation (Amersham Biosciences) selected spots were automatically cut from the gels, destained and enzymatically digested with trypsin. The tryptic peptides were then spotted onto a MALDI target plate. The MALDI target plates were loaded in a Micromass [email protected] MALDI-TOF mass spectrometer (Waters, Milford, USA) for analysis of the peptide masses.

Database search

Peptide masses retrieved from MALDI-TOF analysis spectra were submitted to a database (Mascot) for protein identification.

Results and Discussion

The rats receiving an intradermal injection of native type II collagen began to exhibit swelling of the hind paws in approximately 15-17 days, with maximum swelling occurring at days 21-25. Thereafter, the inflammation subsided slightly and remained constant until day 30. Then the hind paws were measured. Each treatment reduced inflammation, but both celecoxib and methotrexate prevented bone loss adjacent to inflamed joints and significantly decreased bone resorption. In contrast, no treatment affected bone formation parameters.

Some important proteins of interest in arthritis are labelled on the 2-d gel picture (Figure 1). The analysis of serum protein profiles from 2-d gels of normal and arthritic rats clearly shows that several proteins are up-regulated and several proteins are down regulated in arthritic animals compared to normal animals (Figure 2, Tables 1 and 2). A pie chart (Figure 3) shows the protein pattern observed in this study and their distribution. We can see that some proteins are differentially expressed between control and arthritis and some proteins are common between these conditions. Both Celecoxib and Methotrexate are found to be effective in inhibiting some of the proteins that are responsible for arthritis and are over expressed in arthritic condition. The 2-d gel serum protein patterns of celecoxib treated and methotrexate treated rats are shown along with normal and arthritis serum profiles (Figure 4).

pharmacogenomics-pharmacoproteomics-rat-serum

Figure 1: Proteins from rat serum that are of significance in arthritic condition are labeled on the 2-d gel.

pharmacogenomics-pharmacoproteomics-protein-profiles

Figure 2: 2-d gel electrophoresis protein profiles between A) Normal and B) Arthritis rat sera. Proteins separated on 4-7 IPG strips.

pharmacogenomics-pharmacoproteomics-arthritic-sera

Figure 3: Image Analysis of some proteins analyzed after 2-d gel electrophoresis. Image shows proteins that are differentially expressed between normal and arthritic conditions and proteins that are common in normal and arthritic sera.

pharmacogenomics-pharmacoproteomics-arthritic-protein

Figure 4: 2-d gel showing the effects of Celecoxib and Methotrexate on arthritic protein profiles.

Spot no Swiss prot ID Protein identified MW
2304 P97776 A disintegrin and metalloproteinase domain 18 48199
7901 Q91ZY8 SNAP-25-interacting RING finger protein 79206
7405 Q9Z1A5 Amyloid protein-binding protein 1 60382
7610 P55063 Heat shock protein 1A 70549
5904 P41738 Aryl hydrocarbon receptor [Precursor] 96226
5201 P36506 MAP kinase kinase 2 44281
6911 Q63788 Phosphatidylinositol 3-kinase regulatory beta subunit 85000
7704 P28573 Sodium-dependent proline transporter 71090
4307 Q63639 Retinaldehyde-specific dehydrogenase type 2 54739
6909 P55063 Heat shock 70 kDa protein 3 70549
7613 P05178 Cytochrome P450 2C6 56002
7502 Q02955 Interleukin-1 receptor, type I [Precursor] 66758
4903 P13596 Neural cell adhesion molecule 1 94658
8102 P15473 Insulin-like growth factor binding protein 3 31680
6209 P19945 60S acidic ribosomal protein 34215
5512 P18588 Interferon-induced GTP-binding protein Mx1 74469
3615 Q63616 Vacuolar protein sorting 33B 70693
6412 P33274 Cytochrome P450 4F1 59868
7606 Q6UE39 Polypeptide N-acetylgalactosaminyltransferase 63948
7512 P80204 TGF-beta receptor type I 55999
7408 P12939 Cytochrome P450 57076
4202 P02571 Gamma-actin 41793
4110 P63086 Mitogen-activated protein kinase 1 41275
9102 Q63199 Tumor necrosis factor receptor superfamily member 6 (Precursor) 36835
3108 Q9R1T3 Cathepsin Z 34194
7107 P46418 Glutathione S-transferase Yc-2 25216
7508 P49088 Asparagine synthetase 64000
3603 Q02955 Interleukin-1 receptor, type I 66758
2108 P06300 Proenkephalin B 28078
7407 Q02955 Interleukin-1 receptor, type I 66758
4108 Q02346 Myoblast determination protein 1 34359
4509 O88599 Myosin-binding protein H 52656
1910 P24054 SPARC-like protein 1 [Precursor] 70633
5302 Q99PW5 Sialidase 3 46980
5409 O08628 Procollagen C-proteinase enhancer protein 50185
4206 Q63199 Tumor necrosis factor receptor superfamily member 6 36835

Table 1: Protein up-regulated more than 2-fold in Arthritis condition.

SPOT NO. SWISSPROT ID PROTEIN IDENTIFIED MW
5307 P17246 Transforming growth factor beta 1 44329
5301 Q8K5E0 Lysophosphatidic acid receptor 40286
5402 P49001 Bone morphogenetic protein 2 precursor 60000
1903 O70531 Sulfate transporter 82027
510 P50430 Protein-arginine deiminase type I 53320
5308 P50430 Arylsulfatase B [Fragment] 47002
5205 O70210 Cartilage leucine-rich protein 40403
509 Q07116 Sulfite oxidase 54354
1102 P37996 ADP-ribosylation factor-like protein 3 20456
9208 P08033 Gap junction beta-1 protein 32003
507 P50137 Transketolase 67643
603 P20781 Glycine receptor beta chain 55927
504 Q6P6V1 Polypeptide N-acetylgalactosaminyltransferase 11 69039
2303 P54313 G protein beta 2 subunit 37331
9207 O55145 Fractalkine Precursor 41976
6208 P53610 Geranylgeranyl transferase type I beta subunit 42414
7001 P07490 Progonadoliberin I [Precursor 10500
4407 Q9JKY3 Zinc finger protein 238 58310
9204 Q9R1A7 Orphan nuclear receptor PXR 49660
6307 O88599 Myosin-binding protein H 52656
3209 Q63495 Advanced glycosylation end product-specific receptor 42663
6204 Q9QX79 Fetuin-B [Precursor] 41532
3103 P13444 Methionine adenosyltransferase 43698
1104 P35738 2-oxoisovalerate dehydrogenase beta subunit, mitochondrial [Precursor] 40561
503 P00185 Cytochrome P450 1A1 59393
2003 P06911 Epididymal secretory protein I 20670
604 O55096 Dipeptidyl-peptidase III 83038
7302 P97711 G protein coupled receptor kinase 6 65962
7302 P06762 Heme oxygenase 1 33005
1105 P07154 Cathepsin L 37660
3310 O34598 Guanine deaminase 51016

Table 2: Proteins down-regulated more than 2-fold in Arthritis condition.

Cathepsin K is a cysteine protease that plays an essential role in osteoclast function and in the degradation of protein components of the bone matrix by cleaving proteins such as collagen type I, collagen type II and osteonectin. Cathepsin K therefore plays a role in bone remodelling and resorption in diseases such as osteoporosis, osteolytic bone metastasis and rheumatoid arthritis. We found increased levels of cathepsin K compared with a healthy control group and found a significant correlation with radiological destruction. Inhibition of different proteins responsible for arthritic condition by celecoxib and Methotrexate Figures 5 (A-F).

pharmacogenomics-pharmacoproteomics-better-inhibitor

Figure 5A: Methotrexate was found to be a better inhibitor of cathepsin compared to celecoxib.

pharmacogenomics-pharmacoproteomics-methotrexate-treatments

Figure 5B: This protein is potentially inhibited upon celecoxib and methotrexate treatments, where celecoxib was found to be more effective compared to methotrexate.

pharmacogenomics-pharmacoproteomics-arthritic-condition

Figure 5C: In our study CRP is significantly up-regulated in arthritic condition and it is better inhibited by celecoxib when compared to methotrexate.

pharmacogenomics-pharmacoproteomics-inhibitory-effect

Figure 5D: The increased levels of IL-6 are effectively inhibited by D both celecoxib and methotrexate treatments, with methotrexate showing more inhibitory effect compared to celecoxib.

pharmacogenomics-pharmacoproteomics-moderate-extent

Figure 5E: Increased levels of IL-2 are found in arthritic sera and it is inhibited to a great extent by celecoxib and to a moderate extent by methotrexate.

pharmacogenomics-pharmacoproteomics-methotrexate

Figure 5F: Celecoxib to be a better inhibitor of MMPs compared to methotrexate.

A valuable approach to monitor arthritis would be by measuring biological markers of cartilage degradation and repair to reflect variations in joint remodeling. One such potential biological marker of arthritis is cartilage oligomeric matrix protein (COMP). In various studies, COMP has shown promise as a diagnostic and prognostic indicator and as a marker of the disease severity and the effect of treatment. We found increased levels of COMP in arthritic sera.

C-reactive protein (CRP) is one of the biomarkers for the diagnosis and assessment of disease activity in rheumatoid arthritis (RA). CRP is not only the by-product of inflammatory response, but also plays proinflammatory and prothrombotic roles.

Interleukin 6 (IL-6) is a pleiotropic cytokine with a pivotal role in the pathophysiology of rheumatoid arthritis (RA). It is found in abundance in the synovial fluid and serum of patients with RA and the level correlates with the disease activity and joint destruction. IL-6 can promote synovitis and joint destruction by stimulating neutrophil migration, osteoclast maturation and vascular endothelial growth factor (VEGF)-stimulated pannus proliferation. IL-6 may also be mediating many of the systematic manifestations of RA including inducing the acute-phase reaction [including C-reactive protein (CRP)], anemia through hecipidin production, fatigue via the hypothalamic-pituitary-adrenal (HPA) axis) and osteoporosis from its effect on osteoclasts. In addition, IL-6 may contribute to the induction and maintenance of the autoimmune process through B-cell maturation and TH-17 differentiation. All of the above makes IL-6 blockade a desirable therapeutic option in the treatment of RA.

IL-2 is generally considered a pro-inflammatory cytokine that exacerbates Th1-mediated disease states, such as autoimmune arthritis.The collagenases, MMP-1 and MMP-13, have predominant roles in RA and because they are rate limiting in the process of collagen degradation. MMP-1 is produced primarily by the synovial cells that line the joints, and MMP-13 is a product of the chondrocytes that reside in the cartilage. In addition to collagen, MMP-13 also degrades the proteoglycan molecule, aggrecan, giving it a dual role in matrix destruction. Expression of other MMPs such as MMP-2, MMP-3 and MMP-9, is also elevated in arthritis and these enzymes degrade non-collagen matrix components of the joints. Significant effort has been expended in attempts to design effective inhibitors of MMP activity and/or synthesis with the goal of curbing connective tissues destruction within the joints. To date, however, no effective clinical inhibitors exist.

Increasing our knowledge of the crystal structures of these enzymes and of the signal transduction pathways and molecular mechanisms that control MMP gene expression may provide new opportunities for the development of therapeutics to prevent the joint destruction seen in arthritis. In our study we studied inhibition of total MMPs by celecoxib and methotrexate treatments.

Conclusion

In conclusion, this study provides a comparative profile of the effects of therapeutic doses of celecoxib and methotrexate on arthritic rats. The results indicate that the two antiarthritics have varying degrees of side effects on bone metabolism, and these findings may help physicians figure out whether appropriate measure will be needed to better prevent the occurrence of osteopenia in RA treatment.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 1309
  • [From(publication date):
    September-2017 - Nov 19, 2018]
  • Breakdown by view type
  • HTML page views : 1221
  • PDF downloads : 88
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri and Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version